Provided by Tiger Fintech (Singapore) Pte. Ltd.

COYA THERAPEUTICS INC

5.69
-0.0900-1.56%
Volume:65.00K
Turnover:372.56K
Market Cap:95.17M
PE:-5.25
High:5.90
Open:5.87
Low:5.66
Close:5.78
Loading ...

Coya Therapeutics Inc. Set to Participate in BTIG Virtual Biotechnology Conference

Reuters
·
Yesterday

Coya Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
09 Jul

Coya Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
09 Jul

Chardan Capital Remains a Buy on Coya Therapeutics, Inc. (COYA)

TIPRANKS
·
01 Jul

Coya Therapeutics Inc - Re-Submits Ind Application to FDA Related to Phase 2 Study of Coya 302 for ALS Treatment - SEC Filing

THOMSON REUTERS
·
01 Jul

Coya Therapeutics Inc. Re-Submits IND to FDA for Phase 2 ALS Study Following Request for Additional Data

Reuters
·
01 Jul

Coya Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
27 Jun

Coya Therapeutics Inc. to Present at iAccess Alpha Virtual Best Ideas Summer Conference

Reuters
·
18 Jun

Coya Therapeutics Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
09 Jun

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (RH) Interleukin-2 (Aldesleukin) Liquid Formulations

THOMSON REUTERS
·
02 Jun

Coya Therapeutics Inc - to Submit Ind for Coya 302 by End of June

THOMSON REUTERS
·
02 Jun

Coya Therapeutics Secures U.S. Patent for Innovative IL-2 Liquid Formulations, Strengthening Pipeline and IP Portfolio

Reuters
·
02 Jun

Coya Therapeutics Inc. to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

Reuters
·
16 May

Press Release: Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Dow Jones
·
13 May

Coya Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Apr

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study With Low-Dose Il-2 and Ctla4-Ig Combination Treatment in Five Patients With Mild to Moderate Frontotemporal Dementia

THOMSON REUTERS
·
24 Apr

Coya Therapeutics Inc - Study Shows Significant Increase in Treg Numbers and Function

THOMSON REUTERS
·
24 Apr

Coya Therapeutics Inc - Ftd Patients Show Minimal to No Cognitive Decline in Study

THOMSON REUTERS
·
24 Apr

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Business Wire
·
24 Apr

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?

Zacks
·
23 Apr